Overview

Dr. Katie Haubrich's research areas include medication use and dosing in children with chronic kidney disease and on dialysis, immunosuppressant pharmacokinetics (how your body deals with the immune-suppressing drugs you need after a transplant), and monitoring for adverse effects of medications in transplant recipients. She is also interested in how pharmacists and health care teams communicate information about medications and treatments to families.

Publications

Valganciclovir prophylaxis delays onset of EBV viremia in high-risk pediatric solid organ transplant recipients
Pediatric Research
DOI: 10.1038/s41390-019-0523-4
04/2020

RELATE: Relationship of limited sampling strategy and adverse effects of mycophenolate mofetil in pediatric renal transplant patients
Pediatric Transplantation
Iona Berger and Kathryn Haubrich and Mary H. H. Ensom and Roxane Carr
DOI: 10.1111/petr.13355
03/2019

Successful treatment of chronic norovirus gastroenteritis with nitazoxanide in a pediatric kidney transplant recipient
Pediatric Transplantation
Kathryn Haubrich and Soren Gantt and Tom Blydt-Hansen
DOI: 10.1111/petr.13186
06/2018

Research

Correlation of limited sampling strategy for mycophenolate in pediatric solid organ transplant patients
Mycophenolate is commonly used as an immunosuppressant in children who have received solid organ transplants to prevent rejection of the graft. Currently therapeutic drug monitoring is recommended as dosage and serum concentration do not correlate well however it is unclear from the literature what the upper limit of the therapeutic range should be and if limited sampling strategies to estimate area under the curve correlates to effectiveness and adverse drug reactions. Objective: To describe the correlation between limited sampling strategy for mycophenolate and clinical effectiveness (adverse drug reactions and signs or organ graft rejection).

Recombinant Growth Hormone Treatment in Children with Chronic Kidney Disease
Recombinant human growth hormone (rhGH) has been shown to support linear growth in children with chronic kidney disease. However, optimal dosing and duration of therapy remains poorly described. Objective: to describe the effectiveness of rhGH therapy on height velocity and height standard deviation score, stratifying by primary renal disease, and the incidence of adverse effects in children managed on rhGH therapy.